• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BI names new chairman of managing directors

BI names new chairman of managing directors

November 9, 2015
CenterWatch Staff

After 24 years of service to Boehringer Ingelheim (BI), Professor Andreas Barner will retire as chairman of the board of managing directors on June 30, 2016, and will move to the company’s shareholders committee.

After completing his doctorate in medicine and mathematics, Barner joined BI in 1992 as head of the medical division. He became a member of the board of managing directors in 1999, and has been chairman since 2009. Christian Boehringer, chairman of the shareholders committee, thanked Barner for his many years of wide-ranging service, during which time he realigned the company’s research, development and medical activities. He was particularly instrumental in further consolidating and expanding Boehringer Ingelheim’s independence as a family-owned company.

He will be succeeded by Hubertus von Baumbach, whom the shareholders have appointed as the new chairman of the board of managing directors. Hubertus von Baumbach completed a banking apprenticeship and the first and second German state legal examinations before going on to receive an M.B.A. from MIT in Cambridge, Mass. He has been a member of the board of managing directors since 2009 and is head of the corporate board division finance. Following periods at Roche in the U.S. and at BI in Canada, he performed various functions in the finance division at BI in Germany.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing